{
  "asset": {
    "name": "KT-485/SAR447971",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": "IRAK4",
    "mechanism": "Second generation IRAK4 degrader",
    "modality": "Oral small molecule degrader",
    "partner": "Sanofi"
  },
  "clinical_development": {
    "current_stage": "Phase 1 (planned)",
    "indications_in_development": [
      "Hidradenitis Suppurativa",
      "AD",
      "RA",
      "Asthma",
      "IBD"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    11,
    51,
    64
  ],
  "_last_extracted": "2026-02-04T13:13:42.035980"
}